China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)
China · Delayed Price · Currency is CNY 18.85
+0.34 (1.84%)
At close: Mar 27, 2026
SHE:300294 Revenue
In the year 2025, China Resources Boya Bio-pharmaceutical Group Co.,Ltd had annual revenue of 2.06B CNY with 18.69% growth. China Resources Boya Bio-pharmaceutical Group Co.,Ltd had revenue of 585.16M in the quarter ending December 31, 2025, with 19.47% growth.
Revenue
2.06B
Revenue Growth
+18.69%
P/S Ratio
4.62
Revenue / Employee
1.06M
Employees
1,938
Market Cap
9.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.06B | 324.18M | 18.69% |
| Dec 31, 2024 | 1.73B | -917.08M | -34.58% |
| Dec 31, 2023 | 2.65B | -106.72M | -3.87% |
| Dec 31, 2022 | 2.76B | 108.17M | 4.08% |
| Dec 31, 2021 | 2.65B | 137.49M | 5.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Aurisco Pharmaceutical | 1.62B |
| Liaoning Chengda Biotechnology | 1.39B |
| Jiangxi Fushine Pharmaceutical | 1.18B |
| Bio-Thera Solutions | 933.69M |
| Daan Gene | 765.48M |
| Sino Biological,Inc. | 660.17M |
| HitGen | 525.57M |